Marinus Pharmaceuticals, Inc. provided earnings guidance for 2024. For the year, company expects U.S. ZTALMY net product revenue guidance of between $32 Million and $34 Million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.385 USD | -3.15% | -4.48% | -87.26% |
05-08 | Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M | MT |
05-08 | Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.26% | 78.54M | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024